Pharming Group Nv (PHAR)

$7.99

-0.51

(-6%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $7.99
    $8.44
    $7.99
    downward going graph

    0.0%

    Downside

    Day's Volatility :5.33%

    Upside

    5.33%

    downward going graph
  • $6.97
    $16.71
    $7.99
    downward going graph

    12.77%

    Downside

    52 Weeks Volatility :58.29%

    Upside

    52.18%

    downward going graph

Returns

PeriodPharming Group NvIndex (Russel 2000)
3 Months
-13.27%
0.0%
6 Months
-33.02%
0.0%
1 Year
-29.17%
0.0%
3 Years
-23.97%
-20.2%

Highlights

Market Capitalization
571.7M
Book Value
$0.31
Earnings Per Share (EPS)
-0.16
Profit Margin
-4.18%
Operating Margin TTM
-29.35%
Return On Assets TTM
-3.53%
Return On Equity TTM
-5.32%
Revenue TTM
258.4M
Revenue Per Share TTM
3.91
Quarterly Revenue Growth YOY
30.7%
Gross Profit TTM
188.1M
EBITDA
-14.3M
Diluted Eps TTM
-0.16
Quarterly Earnings Growth YOY
-0.61
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Pharming Group Nv(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
1
1
1
Sell
00
00
00

Company Financials

FY18Y/Y Change
Revenue
176.8M
↑ 43.77%
Net Income
32.7M
↓ 129.8%
Net Profit Margin
18.5%
↑ 107.72%
FY19Y/Y Change
Revenue
212.1M
↑ 22.49%
Net Income
45.4M
↑ 41.82%
Net Profit Margin
21.41%
↑ 2.91%
FY20Y/Y Change
Revenue
280.9M
↑ 20.63%
Net Income
46.4M
↓ 6.9%
Net Profit Margin
16.53%
↓ 4.88%
FY21Y/Y Change
Revenue
215.0M
↓ 16.88%
Net Income
18.1M
↓ 57.62%
Net Profit Margin
8.43%
↓ 8.1%
FY22Y/Y Change
Revenue
220.3M
↑ 8.31%
Net Income
14.6M
↓ 14.52%
Net Profit Margin
6.65%
↓ 1.78%
FY23Y/Y Change
Revenue
245.3M
↑ 19.3%
Net Income
-10.5M
↓ 177.14%
Net Profit Margin
-4.3%
↓ 10.95%
Q4 FY22Q/Q Change
Revenue
58.5M
↑ 0.71%
Net Income
-15.7M
↓ 260.75%
Net Profit Margin
-26.78%
↓ 43.56%
Q1 FY23Q/Q Change
Revenue
59.6M
↑ 0.0%
Net Income
-16.0M
↑ 0.0%
Net Profit Margin
-26.78%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
59.9M
↑ 0.51%
Net Income
1.4M
↓ 109.02%
Net Profit Margin
2.4%
↑ 29.18%
Q3 FY23Q/Q Change
Revenue
66.7M
↑ 21.43%
Net Income
3.5M
↑ 162.62%
Net Profit Margin
5.2%
↑ 2.8%
Q4 FY23Q/Q Change
Revenue
81.9M
↑ 22.81%
Net Income
-2.7M
↓ 178.58%
Net Profit Margin
-3.33%
↓ 8.53%
Q1 FY24Q/Q Change
Revenue
81.9M
↑ 0.0%
Net Income
-2.7M
↑ 0.0%
Net Profit Margin
-3.33%
↑ 0.0%
FY18Y/Y Change
Total Assets
280.8M
↑ 23.11%
Total Liabilities
200.0M
↓ 1.14%
FY19Y/Y Change
Total Assets
286.4M
↑ 4.15%
Total Liabilities
155.0M
↓ 20.84%
FY20Y/Y Change
Total Assets
515.5M
↑ 63.95%
Total Liabilities
289.5M
↑ 70.11%
FY21Y/Y Change
Total Assets
449.5M
↓ 5.3%
Total Liabilities
231.2M
↓ 13.26%
FY22Y/Y Change
Total Assets
456.1M
↑ 7.28%
Total Liabilities
236.9M
↑ 8.31%
FY23Y/Y Change
Total Assets
462.9M
↑ 8.7%
Total Liabilities
244.1M
↑ 10.36%
Q4 FY22Q/Q Change
Total Assets
453.1M
↑ 10.64%
Total Liabilities
239.6M
↑ 22.84%
Q1 FY23Q/Q Change
Total Assets
464.3M
↑ 0.66%
Total Liabilities
241.2M
↓ 1.12%
Q2 FY23Q/Q Change
Total Assets
469.0M
↑ 0.94%
Total Liabilities
250.3M
↑ 3.74%
Q3 FY23Q/Q Change
Total Assets
436.5M
↑ 1.55%
Total Liabilities
226.5M
↓ 1.27%
Q4 FY23Q/Q Change
Total Assets
461.4M
↑ 5.72%
Total Liabilities
242.2M
↑ 6.94%
Q1 FY24Q/Q Change
Total Assets
471.0M
↑ 2.07%
Total Liabilities
252.2M
↑ 4.1%
FY18Y/Y Change
Operating Cash Flow
52.8M
↑ 0.75%
Investing Cash Flow
-4.3M
↓ 37.65%
Financing Cash Flow
-23.5M
↑ 426.13%
FY19Y/Y Change
Operating Cash Flow
83.5M
↑ 61.42%
Investing Cash Flow
-28.2M
↑ 569.06%
Financing Cash Flow
-69.8M
↑ 203.33%
FY20Y/Y Change
Operating Cash Flow
111.9M
↑ 22.03%
Investing Cash Flow
-16.8M
↓ 45.76%
Financing Cash Flow
80.4M
↓ 204.82%
FY21Y/Y Change
Operating Cash Flow
40.9M
↓ 60.29%
Investing Cash Flow
-20.3M
↑ 31.33%
Financing Cash Flow
-30.2M
↓ 140.84%
FY22Y/Y Change
Operating Cash Flow
24.5M
↓ 36.62%
Investing Cash Flow
5.7M
↓ 129.63%
Financing Cash Flow
-5.3M
↓ 81.33%
Q4 FY22Q/Q Change
Operating Cash Flow
6.1M
↓ 55.03%
Investing Cash Flow
-427.4K
↑ 33.89%
Financing Cash Flow
297.8K
↓ 114.48%
Q1 FY23Q/Q Change
Operating Cash Flow
6.2M
↑ 0.0%
Investing Cash Flow
-234.5K
↓ 46.12%
Financing Cash Flow
303.2K
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-10.5M
↓ 269.56%
Investing Cash Flow
22.2M
↓ 9546.05%
Financing Cash Flow
-2.9M
↓ 1045.68%

Technicals Summary

Sell

Neutral

Buy

Pharming Group Nv is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Pharming Group Nv
Pharming Group Nv
5.1%
-33.02%
-29.17%
-23.97%
-49.1%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Pharming Group Nv
Pharming Group Nv
NA
NA
NA
0.0
-0.05
-0.04
NA
0.31
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Pharming Group Nv
Pharming Group Nv
Buy
$571.7M
-49.1%
NA
-4.18%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Pharming Group Nv

  • Increasing Revenue

    Revenue is up for the last 11 quarters, 44.63M → 81.86M (in $), with an average increase of 5.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 3.46M → -2.72M (in $), with an average decrease of 89.3% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 89.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 212.1%

Institutional Holdings

  • Silverberg Bernstein Capital Management LLC

    0.03%

Company Information

Organization
Pharming Group Nv
Employees
382
CEO
Dr. Sijmen de Vries M.B.A., M.D.
Industry
Miscellaneous

Discover More

FAQs